Clinica Universidad de Navarra - Madrid /ID# 265299

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors	Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, adenocarcinoma, breast disorder, breast neoplasm, carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, head and neck squamous cell carcinoma, hepatocellular carcinoma, intestinal disorder, liver disorder, neoplasm, rectal disorder, skin disorder, squamous cell carcinoma, triple-negative breast carcinoma	Active, not recruiting	Phase 1	2025-05-25		NCT03821935

Clinical trials